Effect of race/ethnicity on survival in surgically treated intermediate/high risk non‐metastatic clear cell renal carcinoma

Author:

Piccinelli Mattia Luca123ORCID,Garcia Cristina Cano14,Panunzio Andrea15ORCID,Tappero Stefano167ORCID,Barletta Francesco18ORCID,Incesu Reha‐Baris19,Tian Zhe1,Luzzago Stefano210,Mistretta Francesco A.210ORCID,Ferro Matteo2,Saad Fred1,Shariat Shahrokh F.11121314,Graefen Markus9,Briganti Alberto8,Terrone Carlo67,Antonelli Alessandro5,Chun Felix K. H.4,de Cobelli Ottavio210,Musi Gennaro210,Karakiewicz Pierre I.1

Affiliation:

1. Cancer Prognostics and Health Outcomes Unit, Division of Urology University of Montréal Health Center Montréal Québec Canada

2. Department of Urology IEO European Institute of Oncology, IRCCS Milan Italy

3. Scuola di Specializzazione in Urologia Università degli Studi di Milano Milan Italy

4. Department of Urology University Hospital Frankfurt, Goethe University Frankfurt am Main Frankfurt am Main Germany

5. Department of Urology University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy

6. Department of Urology IRCCS Policlinico San Martino Genova Italy

7. Department of Surgical and Diagnostic Integrated Sciences (DISC) University of Genova Genova Italy

8. Division of Experimental Oncology/Unit of Urology URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute Milan Italy

9. Martini‐Klinik Prostate Cancer Center University Hospital Hamburg‐Eppendorf Hamburg Germany

10. Department of Oncology and Haemato‐Oncology Università degli Studi di Milano Milan Italy

11. Department of Urology, Comprehensive Cancer Center Medical University of Vienna Vienna Austria

12. Department of Urology Weill Cornell Medical College New York New York USA

13. Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA

14. Hourani Center of Applied Scientific Research Al‐Ahliyya Amman University Amman Jordan

Abstract

AbstractPurposeIt is unknown to what extent 10‐year overall survival of radical nephrectomy treated intermediate/high‐risk non‐metastatic clear cell renal carcinoma patients differs from age‐ and sex‐matched population‐based controls, especially when race/ethnicity is considered (Caucasian vs. African American vs. Hispanic vs. Asian/Pacific Islander).MethodsWe relied on the SEER database (2004–2018) to identify newly diagnosed radical nephrectomy treated intermediate/high risk non‐metastatic clear cell renal carcinoma patients. For each case, we simulated an age‐ and sex‐matched control relying on Social Security Administration Life Tables with 10 years of follow‐up. We compared overall survival between renal carcinoma cases and population‐based controls. Multivariable competing risks regression models tested for predictors of cancer‐specific mortality versus other‐cause mortality.ResultsOf 6877 radical nephrectomy treated intermediate/high risk non‐metastatic clear cell renal carcinoma patients, 5050 (73%) were Caucasian versus 433 (6%) African American versus 1002 (15%) Hispanic versus 392 (6%) Asian/Pacific Islanders. At 10 years, overall survival difference between radical nephrectomy treated intermediate/high risk non‐metastatic clear cell renal carcinoma patients versus population‐based controls was greatest in African Americans (51% vs. 81%, Δ = 30%), followed by Hispanics (54% vs. 80%, Δ = 26%), Asian/Pacific Islanders (56% vs. 80%, Δ = 24%) and Caucasians (52% vs. 74%, Δ = 22%). In competing risks regression, only African Americans exhibited significantly higher other cause mortality (hazard ratio = 1.3; 95% confidence interval = 1.1 – 1.6; p = 0.01) than others.ConclusionRelative to Life Tables' derived sex‐ and age‐matched controls, radical nephrectomy treated intermediate/high‐risk non‐metastatic clear cell renal carcinoma patients exhibit worse overall survival, with worst overall survival recorded in African Americans of all race/ethnicity groups.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3